Popular Categories
FDA Authorizes Expanded Use for REGEN-COV mAb
The FDA has authorized an additional use for the COVID-19 monoclonal antibody therapeutic REGEN-COV (casirivimab and imdevimab).
Aug 05, 2021 | Guest Author
Medical Reserve Corps
Sustaining and Engaging Volunteers
COVID-19 brought an influx of volunteers to many Medical Reserve Corps units. As pandemic-related missions shift in scale or wind...
Jul 21, 2021 | Beth Hess
Opportunity
Become a Member of NACSD and NACIDD
The National Advisory Committee on Individuals with Disabilities and Disasters (NACIDD) and National Advisory Committee on Seniors and...
Jul 02, 2021 | Beth Hess
COVID-19, OpportunityOpportunity to Participate in LetsTalkCovidVaccine Tailored for Local CommunitiesJohns Hopkins University has funding for five local community health departments to work with them to develop localized tailored messaging for their communities or even segments of a community. Dec 08, 2021 | Beth Hess |
COVID-19FDA Authorizes Expanded Use for REGEN-COV mAbThe FDA has authorized an additional use for the COVID-19 monoclonal antibody therapeutic REGEN-COV (casirivimab and imdevimab). Aug 05, 2021 | Guest Author |
Medical Reserve CorpsSustaining and Engaging VolunteersCOVID-19 brought an influx of volunteers to many Medical Reserve Corps units. As pandemic-related missions shift in scale or wind down, units may be looking for opportunities to continue to engage volunteers. Jul 21, 2021 | Beth Hess |
OpportunityBecome a Member of NACSD and NACIDDThe National Advisory Committee on Individuals with Disabilities and Disasters (NACIDD) and National Advisory Committee on Seniors and Disasters (NACSD) is currently accepting applications from non-federal individuals with the expertise needed to provide diverse perspectives on issues critical to these populations and disasters to fill seven new voting member positions within each committee Jul 02, 2021 | Beth Hess |
Subscribe Today
Sign Up for the E-mail Digests
Create an account or login to MyNACCHO and go to "My Subscriptions."
SUBSCRIBE NOW